公开(公告)号：EP1255741A2

公开(公告)日：2002-11-13

申请号：EP01906827.9

申请日：2001-02-01

Applicant: COR THERAPEUTICS, INC.

Inventor： ZHU, Bing-Yan ,  SCARBOROUGH, Robert

IPC: C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  A61K31/497 ,  A61P9/02

CPC classification number: C07D401/12 ,  C07D241/44 ,  C07D401/14

Abstract: Novel compounds of general formula I, including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivative having activity against mammalian factor Xa is described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.

Abstract translation: 描述了具有抗哺乳动物因子Xa活性的通式I的新化合物，包括它们的药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物。 还描述了含有这些化合物的组合物。 这些化合物和组合物可用于体外或体内预防或治疗以不希望的血栓形成为特征的哺乳动物的病症。

公开(公告)号：EP1047699A1

公开(公告)日：2000-11-02

申请号：EP99902148.8

申请日：1999-01-08

Applicant: COR THERAPEUTICS, INC.

Inventor： LAIBELMAN, Alan M. ,  JANTZEN, Hans-Michael ,  CONLEY, Pamela, B. ,  FRETTO, Larry, J. ,  SCARBOROUGH, Robert, M.

IPC: C07D513/04 ,  A61K31/54 ,  C07D513/14 ,  C07D519/00

CPC classification number: C07D513/04

Abstract: The invention relates to novel compounds of formula (I) containing fused heterocyclic ring systems which are effective platelet ADP receptor inhibitors. Such compounds including pharmaceutically acceptable salts are useful in various pharmaceutical compositions for the prevention and/or treatment of cardiovascular disease particularly those related to thrombosis.

公开(公告)号：EP0631501B1

公开(公告)日：2000-08-30

申请号：EP93908307.7

申请日：1993-03-11

Applicant: COR THERAPEUTICS, INC.

Inventor： SINHA, Uma ,  WOLF, David, L.

IPC: A61K35/78 ,  A61K38/56 ,  A61K38/36 ,  A61K39/395 ,  C07K14/745

CPC classification number: C12N9/6432 ,  A61K38/1709 ,  A61K38/47 ,  C07K14/42 ,  C07K14/745 ,  C07K16/36 ,  C12Y304/21006 ,  Y10S436/827

Abstract: Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an α2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity.

公开(公告)号：EP0584082B1

公开(公告)日：2000-05-31

申请号：EP92906305.5

申请日：1992-01-28

Applicant: COR THERAPEUTICS, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： ESCOBEDO, Jaime, A. ,  WILLIAMS, Lewis, T. ,  WOLF, David ,  TOMLINSON, James, E. ,  FRETTO, Larry, J. ,  GIESE, Neill, A.

IPC: C12N15/12 ,  C12N5/10 ,  C12Q1/68 ,  C07K14/475 ,  C07K14/71 ,  A61K38/18

CPC classification number: C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2319/00

Abstract: Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening or ligand analogues.

公开(公告)号：EP0994892A1

公开(公告)日：2000-04-26

申请号：EP98938486.2

申请日：1998-08-11

Applicant: COR THERAPEUTICS, INC.

Inventor： ZHU, Bing-Yan ,  SCARBOROUGH, Robert, M.

IPC: C07K5/06 ,  A61K38/05

CPC classification number: C07K5/06139 ,  A61K38/00

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders and have formula (I).

Abstract translation: 公开了具有抗哺乳动物因子Xa活性的新化合物，其盐及其组合物。 该化合物在体外或体内用于预防或治疗凝血病症并具有式（I）。

公开(公告)号：EP0977773A1

公开(公告)日：2000-02-09

申请号：EP98914658.4

申请日：1998-04-13

Applicant: COR THERAPEUTICS, INC.

Inventor： SU, Ting ,  ZHU, Bing-Yan ,  SCARBOROUGH, Robert, M.

IPC: C07K5/06 ,  A61K38/05

CPC classification number: C07K5/06139 ,  A61K38/00 ,  C07K5/06078 ,  C07K5/06086

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

公开(公告)号：EP0942931A2

公开(公告)日：1999-09-22

申请号：EP97952309.0

申请日：1997-11-21

Applicant: COR THERAPEUTICS, INC.

Inventor： JENKINS, Alison, L. ,  PHILLIPS, David, R.

IPC: A61K45 ,  A61K38 ,  A61P7 ,  A61P9 ,  A61P21 ,  A61P29 ,  A61P35 ,  C07K14

CPC classification number: C07K14/70546 ,  A61K38/00 ,  C07K14/70557

Abstract: The present invention describes a direct interaction between myosin and the cytoplasmic domain of membrane proteins, particularly the phosphorylated cytoplasmic domains of the β-subunit of integrins. The invention provides methods of identifying agents which block integrin binding to myosin, methods of using agents which block integrin binding to myosin to modulate biological and pathological processes, and provides agents that block integrin mediated binding to myosin and thereby modulate related cellular or cellular component movement.

公开(公告)号：EP0939815A1

公开(公告)日：1999-09-08

申请号：EP97949458.0

申请日：1997-11-18

Applicant: COR THERAPEUTICS, INC.

Inventor： LI, Shengfeng ,  PHILLIPS, David, R.

IPC: G01N33 ,  A61K45 ,  A61P7 ,  A61P29 ,  A61P35 ,  C07K14 ,  C07K16 ,  C07K17 ,  C12N1 ,  C12N5 ,  C12N15 ,  C12P21 ,  C12Q1 ,  A61K38

CPC classification number: C07K14/47 ,  A61K38/00

Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to β3 integrins, αIIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.

公开(公告)号：EP0932608A1

公开(公告)日：1999-08-04

申请号：EP97911745.0

申请日：1997-10-10

Applicant: COR THERAPEUTICS, INC.

Inventor： ZHU, Bing-Yan ,  SCARBOROUGH, Robert, M.

IPC: A61K38 ,  A61P7 ,  A61P9 ,  C07D417 ,  C07F5 ,  C07K5

CPC classification number: C07D417/12 ,  C07F5/025

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

公开(公告)号：EP0804452A4

公开(公告)日：1998-08-12

申请号：EP94925135

申请日：1994-07-26

Applicant: COR THERAPEUTICS INC

Inventor： SCARBOROUGH ROBERT M ,  SUNDELIN JOHAN

IPC: C12N15/09 ,  A61K38/00 ,  A61K48/00 ,  C07H21/04 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  C07K14/72 ,  C07K16/28 ,  C12N5/10 ,  C12P21/02 ,  C12R1/91 ,  C07H21/00 ,  C07K2/00 ,  C07K7/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K7/08 ,  C07K14/723

Abstract: The DNA encoding the C140 cell surface receptor has been cloned and sequenced. The availability of this DNA permits the recombinant production of the C140 receptor which can be produced at cell or oocyte surfaces and is useful in assay systems both for the detection of substances which affect its activity, including agonists and antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in these assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof.